vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Purple Innovation, Inc. (PRPL). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $140.7M, roughly 1.3× Purple Innovation, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -2.3%, a 3.9% gap on every dollar of revenue. On growth, Purple Innovation, Inc. posted the faster year-over-year revenue change (9.1% vs 5.0%). Over the past eight quarters, Purple Innovation, Inc.'s revenue compounded faster (8.3% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Purple Carrot is a Needham, Massachusetts-based, and 100% plant-based meal kit company. Founded by Andy Levitt, it offers both prepared meals as well as meal kits to subscribers weekly. As stated in a 2022 article in Cosmopolitan, “each Purple Carrot meal kit results in 72% less carbon being released into the atmosphere as compared to the standard American meal.”
PCRX vs PRPL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $140.7M |
| Net Profit | $2.9M | $-3.2M |
| Gross Margin | — | 41.9% |
| Operating Margin | 3.9% | -1.6% |
| Net Margin | 1.6% | -2.3% |
| Revenue YoY | 5.0% | 9.1% |
| Net Profit YoY | — | 62.1% |
| EPS (diluted) | $0.07 | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $140.7M | ||
| Q3 25 | $179.5M | $118.8M | ||
| Q2 25 | $181.1M | $105.1M | ||
| Q1 25 | $168.9M | $104.2M | ||
| Q4 24 | $187.3M | $129.0M | ||
| Q3 24 | $168.6M | $118.6M | ||
| Q2 24 | $178.0M | $120.3M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $-3.2M | ||
| Q3 25 | $5.4M | $-11.7M | ||
| Q2 25 | $-4.8M | $-17.3M | ||
| Q1 25 | $4.8M | $-19.1M | ||
| Q4 24 | — | $-8.5M | ||
| Q3 24 | $-143.5M | $-39.2M | ||
| Q2 24 | $18.9M | $27.0K |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 41.9% | ||
| Q3 25 | 80.9% | 42.8% | ||
| Q2 25 | 77.4% | 35.9% | ||
| Q1 25 | 79.7% | 39.4% | ||
| Q4 24 | 78.7% | 42.9% | ||
| Q3 24 | 76.9% | 29.7% | ||
| Q2 24 | 75.1% | 40.7% |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | -1.6% | ||
| Q3 25 | 3.5% | -10.2% | ||
| Q2 25 | 4.7% | -13.5% | ||
| Q1 25 | 1.2% | -13.9% | ||
| Q4 24 | 13.2% | -6.0% | ||
| Q3 24 | -82.8% | -39.5% | ||
| Q2 24 | 15.9% | -12.1% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | -2.3% | ||
| Q3 25 | 3.0% | -9.9% | ||
| Q2 25 | -2.7% | -16.5% | ||
| Q1 25 | 2.8% | -18.4% | ||
| Q4 24 | — | -6.6% | ||
| Q3 24 | -85.1% | -33.1% | ||
| Q2 24 | 10.6% | 0.0% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $0.03 | ||
| Q3 25 | $0.12 | $0.11 | ||
| Q2 25 | $-0.11 | $0.16 | ||
| Q1 25 | $0.10 | $0.18 | ||
| Q4 24 | $0.38 | $0.08 | ||
| Q3 24 | $-3.11 | $0.36 | ||
| Q2 24 | $0.39 | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $24.3M |
| Total DebtLower is stronger | — | $126.7M |
| Stockholders' EquityBook value | $653.9M | $-29.7M |
| Total Assets | $1.2B | $296.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $24.3M | ||
| Q3 25 | $246.3M | $32.4M | ||
| Q2 25 | $445.9M | $34.2M | ||
| Q1 25 | $493.6M | $21.6M | ||
| Q4 24 | $484.6M | $29.0M | ||
| Q3 24 | $453.8M | $23.4M | ||
| Q2 24 | $404.2M | $23.4M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $126.7M | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | $70.7M | ||
| Q3 24 | — | $50.8M | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $-29.7M | ||
| Q3 25 | $727.2M | $-26.9M | ||
| Q2 25 | $757.8M | $-15.6M | ||
| Q1 25 | $798.5M | $1.3M | ||
| Q4 24 | $778.3M | $20.2M | ||
| Q3 24 | $749.6M | $28.0M | ||
| Q2 24 | $879.3M | $66.4M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $296.3M | ||
| Q3 25 | $1.3B | $302.1M | ||
| Q2 25 | $1.5B | $303.8M | ||
| Q1 25 | $1.6B | $293.8M | ||
| Q4 24 | $1.6B | $307.8M | ||
| Q3 24 | $1.5B | $309.3M | ||
| Q2 24 | $1.6B | $362.1M |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | 3.50× | ||
| Q3 24 | — | 1.82× | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-5.8M |
| Free Cash FlowOCF − Capex | — | $-7.8M |
| FCF MarginFCF / Revenue | — | -5.5% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-41.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $-5.8M | ||
| Q3 25 | $60.8M | $-968.0K | ||
| Q2 25 | $12.0M | $-4.0M | ||
| Q1 25 | $35.5M | $-23.1M | ||
| Q4 24 | $33.1M | $6.8M | ||
| Q3 24 | $53.9M | $1.1M | ||
| Q2 24 | $53.2M | $-8.9M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $-7.8M | ||
| Q3 25 | $57.0M | $-1.8M | ||
| Q2 25 | $9.3M | $-7.0M | ||
| Q1 25 | $26.9M | $-25.3M | ||
| Q4 24 | $31.0M | $5.7M | ||
| Q3 24 | $49.8M | $101.0K | ||
| Q2 24 | $51.6M | $-11.0M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | -5.5% | ||
| Q3 25 | 31.7% | -1.5% | ||
| Q2 25 | 5.1% | -6.6% | ||
| Q1 25 | 15.9% | -24.3% | ||
| Q4 24 | 16.6% | 4.4% | ||
| Q3 24 | 29.6% | 0.1% | ||
| Q2 24 | 29.0% | -9.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 1.4% | ||
| Q3 25 | 2.2% | 0.7% | ||
| Q2 25 | 1.5% | 2.8% | ||
| Q1 25 | 5.1% | 2.2% | ||
| Q4 24 | 1.1% | 0.8% | ||
| Q3 24 | 2.4% | 0.9% | ||
| Q2 24 | 0.9% | 1.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | -330.22× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
